Original Publication Date: 1 November, 2014
Publication / Source: Future Oncology
Authors: Roberta M Johnke, Jennifer A Sattler, Ron R Allison
Only two radioprotective compounds, amifostine and palifermin, currently have the US FDA approval for use in radiation therapy. However, several agents have been reported that show therapeutic promise. Many of these agents are free radical scavengers/antioxidants. Superoxide dismutase and superoxide dismutase mimetics, nitroxides and dietary antioxidants are all being investigated.